CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

This clinical study investigates a novel treatment option for adolescents and adults with acute B-lymphoblastic leukemia (B-ALL). While allogeneic hematopoietic stem cell transplantation (HSCT) is a standard therapy for leukemia, some patients are ineligible due to factors such as age, underlying medical conditions, or the absence of a suitable donor. For these individuals, CD19 CAR-T cell therapy is being evaluated as a potential consolidation therapy.

NCT Number	NCT07072494
Lead Sponsor	Zhujiang Hospital
Conditions	Acute Lymphoblastic Leukemia
Enrollment	30 participants
Start Date	2025-07-19
Primary Completion	2027-03-19 (estimated)
Study Completion	2027-08-19 (estimated)
Updated on ClinicalTrials.gov	2025-07-18